Gout is a metabolic disorder characterized by elevated uric acid levels in the body, associated with painful arthritis, tophi and nephropathy. Febuxostat, an antigout drug that is currently approved in many countries for the treatment of gout. It is a BCS class II drug. It exhibits poor bioavailability about 49% which is attributed to its poor solubility. The present work was aimed to overcome these two limitations poor bioavailability and poor solubility. Febuxostat β-Cyclodextrin complex was prepared and characterized by FTIR and DSC studies. In-vitro studies showed that the solubility and dissolution rate of Febuxostat was significantly improved by complexation with β-Cyclodextrin with respect to drug alone. The inclusion complexes with β-Cyclodextrin was prepared by kneading method show highest solubility (378.77%). The Febuxostat containing tablets was prepared by direct compression method using different ingredients such as crosspovidone, crosscarmellose, locust bean gum, lactose, microcrystalline cellulose. Prepared tablets were evaluated for thickness, uniformity of weight, hardness, friability, wetting time, in-vitro disintegration time, drug content and in vitro drug release. The formulation of Locust Bean Gum super-disintegrant in the concentration of (10 %) i.e. F9 batch gives best results. Formulation F9 of Locust Bean Gum superdisintegrant required minimum disintegration time, wetting time as compared to formulations of Crosspovidone and Crosscarmellose with same concentration. So it can be concluded that Febuxostat can be successfully complexed with β-cyclodextrin to prepare fast disintegrating tablet and showed enhanced dissolution rate.